Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Moderna says commercial path remains clear despite unfavorable patent ruling

Moderna isn’t aware of any IP barriers to its products, including its COVID-19 vaccine, after a PTAB decision on Thursday shaved more than $3 billion off its market cap. The

Read the full 305 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE